Furthermore, the in vivo evidence revealed that the disruption of the binding between SENP6 and Nrf2 using the Tat‐Nrf2 peptide leads to a significant decrease in brain injury and alleviated neurological outcomes in mice after ischemic stroke. The gene discussed is TAT; the disease is ischemic stroke.